Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Combination Therapy With Nivolumab (Anti-Pd-1 Monoclonal Antibody): A New Era in Tumor Immunotherapy Publisher Pubmed



Abedi Kiasari B1 ; Abbasi A2 ; Ghasemi Darestani N3 ; Adabi N4 ; Moradian A5 ; Yazdani Y6 ; Sadat Hosseini G7 ; Gholami N8 ; Janati S9
Authors
Show Affiliations
Authors Affiliations
  1. 1. Virology Department, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
  2. 2. Faculty of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Department of Biology, Faculty of Basic Sciences, Neyshabour University of Science and Research, Neyshabur, Iran
  5. 5. Department of Pharmacology and Toxicology, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
  6. 6. Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
  7. 7. Department of Medical Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  8. 8. Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
  9. 9. Faculty of Basic Science and Advanced Technologies in Biology, University of Science and Culture, Tehran, Iran

Source: International Immunopharmacology Published:2022


Abstract

Immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1 or CD279) have noticeably improved the treatment landscape of advanced cancer patients. Nivolumab, the most well-known genetically engineered anti-PD-1 monoclonal antibody (mAb), promotes anti-tumor immunity and shows excellent capability for treating various cancers, particularly lung cancer, renal cancer, and melanoma. Systemic administration of nivolumab could inspire durable therapeutic responses not typically seen with traditional cytotoxic anti-cancer agents. However, nivolumab monotherapy is ineffective in 60–70 percent of patients. The mechanisms leading to both primary and acquired resistance to PD-1/PD-L1 inhibition are varied and multifactorial. Recently, the rationality of adding other conventional therapies such as chemo-radiotherapy and targeted therapies such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and VEGF/VEGFR inhibitors to nivolumab has strongly been verified. These regimens overcome cancer resistance and thus boost nivolumab efficacy in cancer patients. Herein, we discuss the current status of the combination therapy with nivolumab in cancer patients, with a particular focus on the recent clinical reports. © 2022 Elsevier B.V.
Other Related Docs
14. Oncolytic Virotherapy Improves Immunotherapies Targeting Cancer Stemness in Glioblastoma, Biochimica et Biophysica Acta - General Subjects (2024)
16. Recent Progress in Cancer Immunotherapy: Application of Nano-Therapeutic Systems, Journal of Drug Delivery Science and Technology (2024)
21. Advances in Natural Killer Cell Therapies for Breast Cancer, Immunology and Cell Biology (2023)
34. Expression of Nectin-4 and Pd-L1 in Upper Tract Urothelial Carcinoma, International Journal of Molecular Sciences (2020)